Stay updated with breaking news from Nasdaq imgn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com started coverage on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a research note issued to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on IMGN. Piper Sandler restated a neutral rating and set a $31.00 price target (up […] ....
StockNews.com initiated coverage on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a report published on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. A number of other brokerages have also issued reports on IMGN. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ImmunoGen in a research note on Thursday, […] ....
Algert Global LLC purchased a new stake in ImmunoGen, Inc. (NASDAQ:IMGN – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 180,317 shares of the biotechnology company’s stock, valued at approximately $2,862,000. Algert Global LLC owned approximately 0.07% of ImmunoGen at the […] ....
Rafferty Asset Management LLC boosted its position in ImmunoGen, Inc. (NASDAQ:IMGN – Free Report) by 68.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 566,985 shares of the biotechnology company’s stock after purchasing an additional 229,699 shares during the period. Rafferty Asset Management LLC owned about […] ....
StockNews.com initiated coverage on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets reaffirmed a market perform rating and set a […] ....